Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Despite alternatives, addictive drugs most often prescribed for sleep problems

01.06.2005


Nearly one out of two visits to a doctor’s office for help with a sleep disorder result in the prescription of potentially addictive medications, a new study reports.

Office visits by older patients and those with publicly funded health insurance plans were nearly twice as likely to result in the prescription of these kinds of medications.

The drugs, called benzodiazepines, are often a cheaper alternative to some newer types of medicines that don’t have the same potentially addictive side effects, said Rajesh Balkrishnan, the study’s lead author and the Merrell Dow professor of pharmacy at Ohio State University . “Some of the most vulnerable populations in the United States are at greater risk of receiving prescription sleep medication with a high abuse potential,” he said.



The study, which appears in the current issue of the journal Sleep, includes data from 94.6 million office visits in the United States over a six-year period. Patients included in the data set sought help for sleep-related difficulties in outpatient physician offices. Balkrishnan and his colleagues gathered six years of outpatient office visit data – from 1996 to 2001 – from the National Ambulatory Medical Care Survey (NAMCS). The NAMCS includes information on patient demographics, the reason for a visit, a patient’s diagnosis, the medication prescribed and the therapeutic and preventive services recommended during that visit. The majority of patients went to family practice physicians, internal medicine providers or psychiatrists. Using information from the NAMCS, the researchers analyzed the treatment patterns of patients 18 and older who reported sleep problems.

Nearly two-thirds of those visits resulted in medication prescriptions for a person’s sleep difficulties, and three-quarters of those prescriptions were for a benzodiazepine. (Five of the 13 kinds of benzodiazepines on the market in the United States are indicated for treating insomnia.) The other 25 percent of patient visits for sleep disorders ended with prescriptions for non-benzodiazepine medications.

Benzodiazepines were widely prescribed for anxiety and other stress-related problems in the 1960s and 1970s. These drugs, which have a calming effect on the nervous system, are still prescribed as muscle relaxants and tranquilizers. (Valium is one example of a benzodiazepine, although it is not recommended for treating insomnia in the United States.) “Benzodiazepines are usually effective for just a few weeks when used to treat insomnia. But addiction can develop relatively quickly”, Balkrishnan said. “A person can develop a strong psychological and physical dependence on these drugs in a short time, and experience severe withdrawal-like symptoms once he stops taking the medication,” he said.

Office visits by people 50 and older were about 5 times as likely to result in a drug treatment for sleep problems as were visits by 18- to 34-year-olds. And people 65 and older were twice as likely as the 18- to 34-year-olds to receive prescriptions for benzodiazepines. Visits by patients with Medicare or Medicaid – the federally subsidized health insurance plans – were also twice as likely to result in benzodiazepine prescriptions as visits by patients with private health insurance.

Psychiatrists were four times as likely to prescribe newer non-benzodiazepine drugs during patient visits compared to family practice and internal medicine physicians. “Psychiatrists may be more informed than other kinds of doctors about newer, non-benzodiazepine drugs,” Balkrishnan said. “Or psychiatrists may see patients with more complex problems in whom other therapies such as over-the-counter medications have failed. “Overall, the study suggests that some physicians do consider other options before jumping to prescribe a drug to treat sleep problems,” he said.

But many health care providers don’t take public health insurance, Balkrishnan said. This means that these patients, regardless of their age, are more likely to receive cheaper benzodiazepines as treatments for their sleep problems.

And elderly people, 65 and older, with private health insurance were more likely to receive benzodiazepines. “We need to understand the reasons for these disparities in order to stop this trend,” Balkrishnan said. “There needs to be a move toward a more uniform prescription system – at least for certain types of medications. “One possibility is to create guidelines that say let’s reserve the most addictive benzodiazepines for patients for whom every other kind of treatment has been unsuccessful.”

While the study did not look at the types of non-drug treatments prescribed to treat sleep disorders, such as behavioral therapy, the researchers found that nearly half (48 percent) of patient visits resulted in a drug prescription, while 14 percent of the office visits resulted in a combined prescription of medication and behavioral therapy. Just five percent of patient visits resulted in prescribed behavioral therapy only.

The study was funded by a grant from Takeda Pharmaceuticals of North America, Inc., Lincolnshire, Ill. The study does not discuss any specific products of the sponsor company.

Rajesh Balkrishnan | EurekAlert!
Further information:
http://www.osu.edu

More articles from Studies and Analyses:

nachricht Do microplastics harbour additional risks by colonization with harmful bacteria?
05.04.2018 | Leibniz-Institut für Ostseeforschung Warnemünde

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>